Literature DB >> 6217933

Recovery of humoral and cellular immunity by soluble mediators after 5-fluorouracil-induced immunosuppression.

V J Merluzzi, K Last-Barney, B M Susskind, R B Faanes.   

Abstract

5-Fluorouracil (5-FU) administered in daily injections to mice (15-60 mg/kg; subcutaneous) was differentially toxic to helper T cells. Precursors for both antibody forming cells and cytotoxic T lymphocytes (CTL) were spared. 5-FU suppressed the in vitro T cell-dependent antibody response to sheep red blood cells (SRBC). This low response was restored to normal levels by the addition of T cell replacing factor (TRF) or mixed lymphocyte culture (MLC) supernatants to the culture system. T cell-independent antibody responses to TNP-Ficoll or TNP-LPS were not eliminated by 5-FU but, in contrast, were elevated two-four-fold. These results indicate that precursors for antibody forming cells for T cell-dependent and -independent antibody responses were not eliminated by 5-FU, 5-FU administered in the same regimen did not reduce the number of CTL precursors as shown by limiting dilution analysis, but did cause a reduction in the capacity of lymphocytes from pre-treated mice to generate a CTL response in vitro. This low CTL response was restored to control levels by adding Lyt 1+2- T cells or sources of interleukin 2 (IL2) to the culture system, indicating that 5-FU similarly eliminated helper cells for CTL precursor differentiation as well as helper cells for antibody synthesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6217933      PMCID: PMC1536680     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Soluble factors substitute for T-T-cell collaboration in generation of T-killer lymphocytes.

Authors:  J M Plate
Journal:  Nature       Date:  1976-03-25       Impact factor: 49.962

2.  Generation of cytolytic T lymphocytes in vitro. IX. induction of secondary CTL responses in primary long-term MLC by supernatants from secondary MLC.

Authors:  J E Ryser; J C Cerottini; K T Brunner
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

3.  Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.

Authors:  F A Schmid; D J Hutchison; G M Otter; C C Stock
Journal:  Cancer Treat Rep       Date:  1976-01

4.  Experimental models and their clinical correlations.

Authors:  S K Carter; A Goldin
Journal:  Natl Cancer Inst Monogr       Date:  1977-03

5.  Selection of agents for the tumor screen of potential new antineoplastic drugs.

Authors:  H B Wood
Journal:  Natl Cancer Inst Monogr       Date:  1977-03

6.  Macrophage requirement for the in vitro response to TNP Ficoll: a thymic independent antigen.

Authors:  T M Chused; S S Kassan; D E Mosier
Journal:  J Immunol       Date:  1976-06       Impact factor: 5.422

7.  Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma.

Authors:  M Moore; D E Williams
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

8.  Stimulation of a T-independent primary anti-hapten response in vitro by TNP-lipopolysaccharide (TNP-LPS).

Authors:  D M Jacobs; D C Morrison
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

Review 9.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

10.  Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes.

Authors:  M Röllinghoff; A Starzinski-Powitz; K Pfizenmaier; H Wagner
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

View more
  4 in total

1.  Effects of caloric intake on intestinal mucosal morphology and immune cells in rats treated with 5-Fluorouracil.

Authors:  Mariko Murakami; Norifumi Sato; Katsufumi Tashiro; Tsuyoshi Nakamura; Hiroaki Masunaga
Journal:  J Clin Biochem Nutr       Date:  2009-06-30       Impact factor: 3.114

2.  Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.

Authors:  L M Weiner; G R Hudes; J Kitson; J Walczak; P Watts; S Litwin; P J O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

3.  The antitumor activity and immunosuppressive effects of 5-fluorouracil suppositories in rectal cancer patients.

Authors:  W Adachi; A Sugenoya; N Horigome; C Takahashi; F Iida; J Nakayama
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

4.  Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant chemotherapy for biliary tract cancer: study protocol for a single-centre, open-label, single-arm, historically controlled study.

Authors:  Kimihiko Ueno; Tetsuo Ajiki; Daisuke Tsugawa; Masayuki Akita; Yu Hashimoto; Masahide Awazu; Hideyo Mukubo; Shohei Komatsu; Kaori Kuramitsu; Sachio Terai; Motofumi Tanaka; Hirichika Toyama; Masahiro Kido; Takumi Fukumoto
Journal:  BMJ Open       Date:  2019-08-10       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.